Abbott (NYSE:ABT) said today that it won national reimbursement in Japan for its everolimus-eluting stent, Xience Sierra, which is designed to treat patients with coronary artery disease.
The company’s latest drug-eluting device features a thinner profile, increased flexibility and longer lengths than previous stents, according to Abbott. The healthcare firm said it developed Xience Sierra to help cardiologists treat the complex lesions that make up nearly 70% of cases of coronary artery disease.
Abbott’s Xience Sierra won approval in Japan last month and CE Mark clearance in the European Union in 2017.
“Extensive clinical data and 10 years of real-world experience with the Xience family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available,” Chuck Brynelsen, SVP of Abbott’s vascular business, said in prepared remarks. “National reimbursement of Xience Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives.”
